{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.98","upperLimit":"23.5","value":"4.0"},{"groupId":"OG001","lowerLimit":"1.97","upperLimit":"24.0","value":"4.02"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Cycle 1 Day 1 PK time to maximum plasma drug concentration (Tmax)","dispersionType":"Full Range","groups":[{"description":"Part 1 and Part 2: Patients received a starting dose of 300 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG000","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD"},{"description":"Part 1 and Part 2: Patients received a starting dose of 400 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG001","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD"}],"paramType":"MEDIAN","populationDescription":"Patients enrolled in Part 1 and Part 2 with available samples for PK","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1","title":"Time to Maximum Plasma Drug Concentration (Tmax)","type":"SECONDARY","unitOfMeasure":"hours"}